Talampanel a non-competitive AMPA-antagonist attenuates caspase-3 dependent apoptosis in mouse brain after transient focal cerebral ischemia
- 1 July 2006
- journal article
- Published by Elsevier in Brain Research Bulletin
- Vol. 70 (3) , 260-262
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- The AMPA-antagonist talampanel is neuroprotective in rodent models of focal cerebral ischemiaBrain Research Bulletin, 2005
- Immunohistochemical analysis of protein expression after middle cerebral artery occlusion in miceActa Neuropathologica, 2003
- Non-NMDA mechanism in the inhibition of cellular apoptosis and memory impairment induced by repeated ischemia in ratsBrain Research, 2003
- AMPA receptor‐mediated toxicity in oligodendrocyte progenitors involves free radical generation and activation of JNK, calpain and caspase 3Journal of Neurochemistry, 2002
- Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heartNature Medicine, 2001
- Pathobiology of ischaemic stroke: an integrated viewTrends in Neurosciences, 1999
- Apoptosis and myocardial infarctionBasic Research in Cardiology, 1998
- Prolonged Therapeutic Window for Ischemic Brain Damage Caused by Delayed Caspase ActivationJournal of Cerebral Blood Flow & Metabolism, 1998
- Presence of double-strand breaks with single-base 3' overhangs in cells undergoing apoptosis but not necrosis.Journal of Cell Biology, 1996
- GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responsesNeuron, 1993